8 results on '"Scheffold, Christian"'
Search Results
2. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
- Author
-
George, Daniel J., Hessel, Colin, Halabi, Susan, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, Morris, Michael J., and Choueiri, Toni K.
- Subjects
ANTINEOPLASTIC agents ,CANCER patients ,RENAL cell carcinoma ,RISK assessment ,STATISTICAL sampling ,SURVIVAL ,RANDOMIZED controlled trials ,TREATMENT effectiveness - Abstract
Cabozantinib treatment prolonged progression‐free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158. The phase II CABOSUN trial compared cabozantinib with sunitinib as initial treatment in patients with advanced renal cell carcinoma of intermediate or poor risk. This article presents subgroup analyses by baseline patient characteristics. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
- Author
-
Powles, Thomas, Choueiri, Toni K., Motzer, Robert J., Jonasch, Eric, Pal, Sumanta, Tannir, Nizar M., Signoretti, Sabina, Kaldate, Rajesh, Scheffold, Christian, Wang, Evelyn, Aftab, Dana T., Escudier, Bernard, and George, Daniel J.
- Subjects
RENAL cell carcinoma ,EVEROLIMUS ,METEORS ,BIOMARKERS - Abstract
Wang is employed by Exelixis; and has stock/ownership interests with Exelixis.
Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Competing interests Dr. [Extracted from the article] - Published
- 2021
- Full Text
- View/download PDF
4. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
- Author
-
Apolo, Andrea B., Powles, Thomas, Escudier, Bernard, Burotto, Mauricio, Zhang, Joshua, Simsek, Burcin, Scheffold, Christian, Motzer, Robert J., and Choueiri, Toni K.
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *RENAL cell carcinoma , *RESEARCH , *IPILIMUMAB , *ANTINEOPLASTIC agents , *HEPATOTOXICOLOGY , *RANDOMIZED controlled trials , *NIVOLUMAB , *PATIENT safety , *ALANINE aminotransferase , *ASPARTATE aminotransferase - Abstract
The phase III CheckMate 9ER trial originally included a nivolumab plus ipilimumab plus cabozantinib triplet arm, which was discontinued early due to the evolving treatment landscape for first-line advanced renal cell carcinoma (aRCC). We report an exploratory analysis of patients randomised to the triplet regimen before enrolment discontinuation. Patients with clear-cell aRCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) Q3W for four cycles with once-daily cabozantinib (40 mg), then nivolumab (240 mg) Q2W plus once-daily cabozantinib (40 mg). CheckMate 9ER primary (progression-free survival [PFS] by blinded independent central review [BICR]) and key secondary (overall survival [OS], objective response rate [ORR] by BICR, and safety) endpoints were applied, along with investigator-assessed PFS and ORR. Fifty patients were randomised to the triplet regimen. After a median follow-up of 39.1 months (range, 33.4–44.5), median PFS (95% CI) was 9.9 (5.7–16.8) months by BICR and 13.9 (7.3–24.7) months by investigator; median OS (95% CI) was 37.0 (31.8-not estimable) months. ORR (95% CI) was 44.0% (30.0–58.7; complete response, 8.0%) by BICR and 48.0% (33.7–62.6; all partial responses) by investigator. Grade 3–4 treatment-related adverse events (TRAEs) occurred in 84.0%, most commonly alanine aminotransferase increased (20.0%), aspartate aminotransferase increased (16.0%), and hepatotoxicity (16.0%). Grade 3–4 hepatic immune-mediated AEs occurred in 40.0%. There were no grade 5 TRAEs. These results suggest that the nivolumab plus ipilimumab plus cabozantinib triplet combination has clinical activity in patients with previously untreated aRCC, although monitoring of overlapping toxicities will be important in future studies of this regimen. ClinicalTrials.gov registration: NCT03141177. • Nivolumab + ipilimumab + cabozantinib has clinical activity in untreated aRCC. • Monitoring overlapping toxicities will be important in future studies. • Evaluation of the triplet regimen is ongoing in the phase III COSMIC-313 trial. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
- Author
-
Motzer, Robert J, Powles, Thomas, Burotto, Mauricio, Escudier, Bernard, Bourlon, Maria T, Shah, Amishi Y, Suárez, Cristina, Hamzaj, Alketa, Porta, Camillo, Hocking, Christopher M, Kessler, Elizabeth R, Gurney, Howard, Tomita, Yoshihiko, Bedke, Jens, Zhang, Joshua, Simsek, Burcin, Scheffold, Christian, Apolo, Andrea B, and Choueiri, Toni K
- Subjects
- *
RENAL cell carcinoma , *PYRIDINE , *RESEARCH , *CLINICAL trials , *MYERS-Briggs Type Indicator , *RESEARCH methodology , *ANTINEOPLASTIC agents , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *KIDNEY tumors , *LONGITUDINAL method , *AMIDES - Abstract
Background: In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously untreated advanced renal cell carcinoma (median follow-up of 18·1 months). Here, we report extended follow-up of overall survival and updated efficacy and safety.Methods: This open-label, randomised, phase 3 trial was done in 125 hospitals and cancer centres across 18 countries. We included patients aged 18 years or older with previously untreated advanced or metastatic clear-cell renal cell carcinoma, a Karnofsky performance status of 70% or higher, measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 assessed by the investigator, any International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic risk category, and available tumour tissue for PD-L1 testing. Patients were randomly assigned (1:1) to nivolumab (240 mg) intravenously every 2 weeks plus cabozantinib (40 mg) orally once daily or sunitinib (50 mg orally) once daily (4 weeks per 6-week cycle). Randomisation, stratified by IMDC risk status, tumour PD-L1 expression, and geographical region, was done by permuted block within each stratum using a block size of four, via an interactive response system. The primary endpoint was progression-free survival by blinded independent central review. Overall survival was a secondary endpoint (reported here as the preplanned final analysis according to the protocol). Efficacy was assessed in all randomly assigned patients; safety was assessed in all patients who received at least one dose of any study drug. This ongoing study, closed to recruitment, is registered with ClinicalTrials.gov, NCT03141177.Findings: Between Sept 11, 2017, and May 14, 2019, 323 patients were randomly assigned to the nivolumab plus cabozantinib group and 328 to the sunitinib group. With an extended follow-up (data cutoff of June 24, 2021; median 32·9 months [IQR 30·4-35·9]), median overall survival was 37·7 months (95% CI 35·5-not estimable) in the nivolumab plus cabozantinib group and 34·3 months (29·0-not estimable) in the sunitinib group (hazard ratio [HR] 0·70 [95% CI 0·55-0·90], p=0·0043) and updated median progression-free survival was 16·6 months (12·8-19·8) versus 8·3 months (7·0-9·7; HR 0·56 [95% CI 0·46-0·68], p<0·0001). Grade 3-4 treatment-related adverse events occurred in 208 (65%) of 320 patients with nivolumab plus cabozantinib versus 172 (54%) of 320 with sunitinib. The most common grade 3-4 treatment-related adverse events were hypertension (40 [13%] of 320 patients in the nivolumab plus cabozantinib group vs 39 [12%] of 320 in the sunitinib group), palmar-plantar erythrodysaesthesia (25 [8%] vs 26 [8%]), and diarrhoea (22 [7%] vs 15 [5%]). Grade 3-4 treatment-related serious adverse events occurred in 70 (22%) of 320 patients in the nivolumab plus cabozantinib group and 31 (10%) of 320 in the cabozantinib group. One additional treatment-related death occurred with sunitinib (sudden death).Interpretation: With extended follow-up and preplanned final overall survival analysis per protocol, nivolumab plus cabozantinib demonstrated improved efficacy versus sunitinib, further supporting the combination in the first-line treatment of advanced renal cell carcinoma.Funding: Bristol Myers Squibb and Ono Pharmaceutical. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
- Author
-
Choueiri, Toni K., Hessel, Colin, Halabi, Susan, Sanford, Ben, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, George, Daniel, and Morris, Michael J.
- Subjects
- *
CANCER patients , *COMMITTEES , *CONFIDENCE intervals , *HEALTH outcome assessment , *RENAL cell carcinoma , *RISK assessment , *SURVIVAL analysis (Biometry) , *PROTEIN-tyrosine kinase inhibitors , *RESEARCH personnel , *DISEASE incidence , *DESCRIPTIVE statistics , *EVALUATION , *THERAPEUTICS - Abstract
Background The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met the primary end-point of improving progression-free survival (PFS) as assessed by investigator. We report PFS by independent radiology review committee (IRC) assessment, ORR per IRC and updated overall survival (OS). Patients and methods Previously untreated patients with advanced RCC of intermediate or poor risk by IMDC criteria were randomised 1:1 to cabozantinib 60 mg daily or sunitinib 50 mg daily (4 weeks on/2 weeks off). Stratification was by risk group and presence of bone metastases. Results A total of 157 patients were randomised 1:1 to cabozantinib (n = 79) or sunitinib (n = 78). Median PFS per IRC was 8.6 months (95% confidence interval [CI] 6.8–14.0) versus 5.3 months (95% CI 3.0–8.2) for cabozantinib versus sunitinib (hazard ratio [HR] 0.48 [95% CI 0.31–0.74]; two-sided p = 0.0008), and ORR per IRC was 20% (95% CI 12.0–30.8) versus 9% (95% CI 3.7–17.6), respectively. Subgroup analyses of PFS by stratification factors and MET tumour expression were consistent with results for the overall population. With a median follow-up of 34.5 months, median OS was 26.6 months (95% CI 14.6–not estimable) with cabozantinib and 21.2 months (95% CI 16.3–27.4) with sunitinib (HR 0.80 [95% CI 0.53–1.21]. The incidence of grade 3 or 4 adverse events was 68% for cabozantinib and 65% for sunitinib. Conclusions In this phase 2 trial, cabozantinib treatment significantly prolonged PFS per IRC compared with sunitinib as initial systemic therapy for advanced RCC of poor or intermediate risk. Trial Registration Number NCT01835158 . [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
- Author
-
Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Tannir, Nizar M, Mainwaring, Paul N, Rini, Brian I, Hammers, Hans J, Donskov, Frede, Roth, Bruce J, Peltola, Katriina, Lee, Jae Lyun, Heng, Daniel Y C, Schmidinger, Manuela, Agarwal, Neeraj, Sternberg, Cora N, McDermott, David F, Aftab, Dana T, Hessel, Colin, Scheffold, Christian, and Schwab, Gisela
- Subjects
- *
EVEROLIMUS , *RENAL cell carcinoma , *CANCER treatment , *PROTEIN-tyrosine kinases , *MEDICATION safety , *DRUG efficacy , *PROGRESSION-free survival , *THERAPEUTICS , *ANTINEOPLASTIC agents , *AMIDES , *COMPARATIVE studies , *KIDNEY tumors , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *PSYCHOLOGICAL tests , *PYRIDINE , *RESEARCH , *RESEARCH funding , *STATISTICAL sampling , *SURVIVAL , *TUMOR classification , *EVALUATION research , *PAIN measurement , *RANDOMIZED controlled trials - Abstract
Background: Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Here, we report the final overall survival results from this study based on an unplanned second interim analysis.Methods: In this open-label, randomised phase 3 trial, we randomly assigned (1:1) patients aged 18 years and older with advanced or metastatic clear-cell renal cell carcinoma, measurable disease, and previous treatment with one or more VEGFR tyrosine-kinase inhibitors to receive 60 mg cabozantinib once a day or 10 mg everolimus once a day. Randomisation was done with an interactive voice and web response system. Stratification factors were Memorial Sloan Kettering Cancer Center risk group and the number of previous treatments with VEGFR tyrosine-kinase inhibitors. The primary endpoint was progression-free survival as assessed by an independent radiology review committee in the first 375 randomly assigned patients and has been previously reported. Secondary endpoints were overall survival and objective response in all randomly assigned patients assessed by intention-to-treat. Safety was assessed per protocol in all patients who received at least one dose of study drug. The study is closed for enrolment but treatment and follow-up of patients is ongoing for long-term safety evaluation. This trial is registered with ClinicalTrials.gov, number NCT01865747.Findings: Between Aug 8, 2013, and Nov 24, 2014, 658 patients were randomly assigned to receive cabozantinib (n=330) or everolimus (n=328). The median duration of follow-up for overall survival and safety was 18·7 months (IQR 16·1-21·1) in the cabozantinib group and 18·8 months (16·0-21·2) in the everolimus group. Median overall survival was 21·4 months (95% CI 18·7-not estimable) with cabozantinib and 16·5 months (14·7-18·8) with everolimus (hazard ratio [HR] 0·66 [95% CI 0·53-0·83]; p=0·00026). Cabozantinib treatment also resulted in improved progression-free survival (HR 0·51 [95% CI 0·41-0·62]; p<0·0001) and objective response (17% [13-22] with cabozantinib vs 3% [2-6] with everolimus; p<0·0001) per independent radiology review among all randomised patients. The most common grade 3 or 4 adverse events were hypertension (49 [15%] in the cabozantinib group vs 12 [4%] in the everolimus group), diarrhoea (43 [13%] vs 7 [2%]), fatigue (36 [11%] vs 24 [7%]), palmar-plantar erythrodysaesthesia syndrome (27 [8%] vs 3 [1%]), anaemia (19 [6%] vs 53 [17%]), hyperglycaemia (3 [1%] vs 16 [5%]), and hypomagnesaemia (16 [5%] vs none). Serious adverse events grade 3 or worse occurred in 130 (39%) patients in the cabozantinib group and in 129 (40%) in the everolimus group. One treatment-related death occurred in the cabozantinib group (death; not otherwise specified) and two occurred in the everolimus group (one aspergillus infection and one pneumonia aspiration).Interpretation: Treatment with cabozantinib increased overall survival, delayed disease progression, and improved the objective response compared with everolimus. Based on these results, cabozantinib should be considered as a new standard-of-care treatment option for previously treated patients with advanced renal cell carcinoma. Patients should be monitored for adverse events that might require dose modifications.Funding: Exelixis Inc. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115–125].
- Author
-
Choueiri, Toni K., Hessel, Colin, Halabi, Susan, Sanford, Ben, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, George, Daniel, and Morris, Michael J.
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *METASTASIS , *RENAL cell carcinoma , *PROGNOSIS , *THERAPEUTICS - Published
- 2018
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resourcesDiscovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.